ArticleProstate cancer and prostatic diseases2026

Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States.

Aidan S Weitzner et al.PubMed ↗Publisher ↗

No numbers read from the abstract.